skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Adverse drug reaction reporting in New Zealand: implications for pharmacists

(2798) Views  (472) Full article downloads

Authors: Monica Zolezzi, Nirasha Parsotam

Published Date January 2005 Volume 2005:1(3) Pages 181 - 188
DOI: http://dx.doi.org/10.2147/TCRM.S

Monica Zolezzi1, Nirasha Parsotam2

1School of Pharmacy, The University of Auckland, Auckland, New Zealand; 2Medication Safety, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand

Abstract: Adverse drug reactions (ADRs) are a significant cause of morbidity and mortality and contribute to the incidence of adverse events, resulting in increased healthcare costs. Healthcare providers need to understand their role and responsibility in the detection, management, documentation, and reporting of ADRs, all essential activities for optimizing patient safety. The purpose of this article is to summarize findings from important ADR literature reviews and describe the components, and extent of participation, of the national ADR reporting program available in New Zealand. A series of recommendations to increase the detection of ADRs is also described.

Keywords: adverse drug reactions, post-marketing surveillance, pharmacists








Readers of this article also read:

Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Progress in the development of a therapeutic vaccine for breast cancer
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
Reliability of an instrument to determine lower limb comfort in professional football
Differential susceptibility of HIV strains to innate immune factors in human cervical-vaginal secretions
Update on vaccine development for renal cell cancer
ABO and rhesus blood group distribution in Kurds
Erratum